all report title image

VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS

Von Willebrand Disease Treatment Market, by Disease Type (Type 1 vWD, Type 2 vWD, Type 3 vWD, and Acquired vWD), by Treatment Type (Desmopressin, Replacement therapies, Contraceptives, Clot-stabilizing medications, and Drugs applied to cuts), and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Dec 2024
  • Code : CMI1154
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Leading Companies

Key players are organizing various symposiums to raise awareness about von Willebrand Disease and to increase brand visibility.

Key players in von Willebrand Disease (vWD) treatment market include Octapharma, Shire Plc, BDI Pharma, Baxalta, Ferring Pharmaceuticals, CSL Behring, and Grifols Therapeutics Inc. In 2017, Octapharma organized a symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress in Berlin to support progress in lifelong treatment for patients with von Willebrand Disease (vWD) and to spread knowledge about their latest replacement therapy WILATE for treatment of von Willebrand Disease.   

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.